Known targets — ChEMBL curated mechanism
CACNA1CCACNA1DCACNA1FCACNA1SDPP4HTR1BHTR1D
The experimentally established mechanism targets of Benzoic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.64 |
| ▸ | ADRB2 | P07550 | 10/20 | 0.59 |
| ▸ | ADRB1 | P08588 | 10/20 | 0.59 |
| ▸ | ADRB3 | P13945 | 10/20 | 0.59 |
| ▸ | PRKCA | P17252 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.47 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.47 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | DAO | P14920 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | SLC1A5 | Q15758 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Benzoic Acid SCHEMBL9956241 | 1.00 | ALDH1A1 (0.64) | ALDH1A1ADRB2ADRB1ADRB3PRKCA | |
| Benzoic Acid SCHEMBL28388934 | 1.00 | ALDH1A1 (0.64) | ALDH1A1ADRB2ADRB1ADRB3PRKCA | |
| Benzoic Acid SCHEMBL136510 | 1.00 | ALDH1A1 (0.64) | ALDH1A1ADRB2ADRB1ADRB3PRKCA | |
| SCHEMBL1866113 | 0.95 | ALDH1A1 (0.70) | ALDH1A1ADRB2ADRB1ADRB3PRKCA | |
| SCHEMBL1866116 | 0.95 | ALDH1A1 (0.70) | ALDH1A1ADRB2ADRB1ADRB3PRKCA | |
| SCHEMBL3391 | 0.95 | ALDH1A1 (0.70) | ALDH1A1ADRB2ADRB1ADRB3PRKCA | |
| SCHEMBL20515564 | 0.93 | ALDH1A1 (0.68) | ALDH1A1ADRB2ADRB1ADRB3PRKCA | |
| SCHEMBL2788016 | 0.93 | MAPT (0.58) | ALDH1A1ADRB2ADRB1ADRB3PRKCA | |
| Methyl Benzoate SCHEMBL29022830 | 0.93 | ADRB2 (0.59) | ALDH1A1ADRB2ADRB1ADRB3PRKCA | |
| Benzyl Benzoate SCHEMBL9296609 | 0.91 | KMT2A (0.64) | ALDH1A1ADRB2ADRB1ADRB3PRKCA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 83 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12514842-B2 | Use of a benzoate containing composition to treat neurodegenerative disorders | RUSH UNIVERSITY MEDICAL CENTER (US) | 2026-01-06 | — | — | US | claimed |
| US-12478598-B2 | Compositions including cinnamic acid and methods of use thereof | RUSH UNIVERSITY MEDICAL CENTER (US) | 2025-11-25 | — | — | US | claimed |
| EP-3999051-B1 | INHALATION DOSAGE FORMS OF GLYCEROL TRIBENZOATE AND/OR GLYCEROL DIBENZOATE FOR USE IN THE TREATMENT OF HUNTINGTON'S DISEASE | UNIV RUSH MEDICAL CENTER (US) | 2025-07-09 | — | — | EP | claimed |
| US-20220313646-A1 | USE OF A BENZOATE CONTAINING COMPOSITION TO TREAT NEURODEGENERATIVE DISORDERS | RUSH UNIVERSITY MEDICAL CENTER | 2022-10-06 | — | — | US | claimed |
| EP-3999051-A2 | USE OF A BENZOATE CONTAINING COMPOSITION TO TREAT NEURODEGENERATIVE DISORDERS | Rush University Medical Center (US) | 2022-05-25 | — | — | EP | claimed |
| CN-114502154-A | Use of benzoate-containing compositions for treating neurodegenerative diseases | 拉什大学医学中心 | 2022-05-13 | — | — | CN | claimed |
| US-20220133664-A1 | COMPOSITIONS INCLUDING CINNAMIC ACID AND METHODS OF USE THEREOF | RUSH UNIVERSITY MEDICAL CENTER | 2022-05-05 | — | — | US | claimed |
| US-11304923-B2 | Use of a benzoate containing composition to treat glycine encephalopathy | RUSH UNIVERSITY MEDICAL CENTER (US) | 2022-04-19 | — | — | US | claimed |
| EP-3930704-A1 | COMPOSITIONS INCLUDING CINNAMIC ACID AND METHODS OF USE THEREOF | Rush University Medical Center (US) | 2022-01-05 | — | — | EP | claimed |
| CN-113473981-A | Cinnamic acid containing compositions and methods of use thereof | 拉什大学医学中心 | 2021-10-01 | — | — | CN | claimed |
| WO-2021011500-A2 | USE OF A BENZOATE CONTAINING COMPOSITION TO TREAT NEURODEGENERATIVE DISORDERS | RUSH UNIVERSITY MEDICAL CENTER (US) | 2021-01-21 | — | — | WO | claimed |
| EP-3094616-B1 | THE USE OF GLYCERYL TRIBENZOATE CONTAINING COMPOSITION IN NEURODEGENERATIVE DISORDERS | UNIV RUSH MEDICAL CENTER (US) | 2020-12-23 | — | — | EP | claimed |
| US-20200281884-A1 | Use of a Benzoate Containing Composition to Treat Glycine Encephalopathy | RUSH UNIVERSITY MEDICAL CENTER (US) | 2020-09-10 | — | — | US | claimed |
| EP-3691630-A1 | THE USE OF A BENZOATE CONTAINING COMPOSITION TO TREAT GLYCINE ENCEPHALOPATHY | Rush University Medical Center (US) | 2020-08-12 | — | — | EP | claimed |
| WO-2019070478-A1 | THE USE OF A BENZOATE CONTAINING COMPOSITION TO TREAT GLYCINE ENCEPHALOPATHY | RUSH UNIVERSITY MEDICAL CENTER (US) | 2019-04-11 | — | — | WO | claimed |
| US-9968582-B2 | Use of a benzoate containing composition in urea cycle disorders and neurodegenerative disorders | RUSH UNIVERSITY MEDICAL CENTER (US) | 2018-05-15 | — | — | US | claimed |
| EP-3094616-A1 | THE USE OF A BENZOATE CONTAINING COMPOSITION IN UREA CYCLE DISORDERS AND NEURODEGENERATIVRE DISORDERS | Pahan, Kalipada (US) | 2016-11-23 | — | — | EP | claimed |
| US-20160331714-A1 | THE USE OF A BENZOATE CONTAINING COMPOSITION IN UREA CYCLE DISORDERS AND NEURODEGENERATIVE DISORDERS | RUSH UNIVERSITY MEDICAL CENTER | 2016-11-17 | — | — | US | claimed |
| US-20160271029-A1 | GLYCERYL AND GLYCOL ACID COMPOUNDS | MARY KAY INC. | 2016-09-22 | — | — | US | claimed |
| WO-2015109215-A1 | THE USE OF A BENZOATE CONTAINING COMPOSITION IN UREA CYCLE DISORDERS AND NEURODEGENERATIVRE DISORDRS | PAHAN KALIPADA (US) | 2015-07-23 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160271029-A1 | GLYCERYL AND GLYCOL ACID COMPOUNDS | GK, MGLL, GLA | ALDH1A1 720/4885ADRB2 2787/4885ADRB1 2313/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.